Clinical Trials


DISCLAIMER:

All of the information and materials contained on this page are intended for general medical and health information and educational purposes only, and are not in any way intended to be used as a substitute for professional medical advice, treatment or care.  You are encouraged to discuss any and all of this information with your physician.  The Ewings Cancer Foundation of Canada makes no guarantees, warranties or representations, implied or expressed, as to the appropriateness, timeliness, accuracy, completeness, and/or usefulness of any of the information presented here.  All specific medical questions which arise as a result of viewing information on this website should be presented to your own physician for review.  The Ewings Cancer Foundation of Canada assumes no risk or obligation for your use of the material on this website.

 

Canadian Clinical Trials
CANADIAN TRIALS


Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours (TOPAZ) (Any Age)

https://clinicaltrials.gov/ct2/show/NCT02303028
or search (CCTG) IND.217 (TOPAZ) at http://portfolio.3ctn.ca


Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors (Ages 1 - 18 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01956669


Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors (Ages 2 - 18 Years)

https://clinicaltrials.gov/show/NCT01858155
or search or search (C17) MEL P1 at http://portfolio.3ctn.ca


Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours (Any Age)

https://clinicaltrials.gov/ct2/show/NCT02343718
or search or search (CCTG) IND.218 (VITORI) at http://portfolio.3ctn.ca


A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02598960


Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (Ages Up to 50 Years)

https://clinicaltrials.gov/ct2/show/study/NCT02306161
or search COG-AEWS1221 at http://portfolio.3ctn.ca/


MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours (I214) (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02285816
or search (CCTG) IND.214 at http://portfolio.3ctn.ca


A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/study/NCT02410512


Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens (Adults Only)

https://clinicaltrials.gov/ct2/show/NCT025374181
or search (CCTG) IND.226 at http://portfolio.3ctn.ca


A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/study/NCT02219724


An Open-Label Study of Atezolizumab in Advanced Solid Tumors (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/study/NCT02458638


To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors (Ages 6 Months - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01962103


Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors (Ages 18 and Older)

https://clinicaltrials.gov/ct2/show/NCT02298959
or search PJC-016/NCI 9676 at http://portfolio.3ctn.ca


A Single-Arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors (Up to 30 Years Old)

https://clinicaltrials.gov/ct2/show/study/NCT02541604


Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02188264


Collecting and Storing Biological Samples From Patients With Ewing Sarcoma (Ages Up to 21 Years)

https://clinicaltrials.gov/ct2/show/study/NCT00899990


Collecting and Storing Tissue From Young Patients With Cancer (Ages Up to 21 Years)

https://clinicaltrials.gov/ct2/show/study/NCT00898755


Copanlisib (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor Patients (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02253420


A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051) (Ages 6 Months - 17 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02332668


A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT) (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02791334


Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours (Ages 18 - 99 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02482311


Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02737475


Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT01989585


Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma (Ages Up to 50 Years)

Search COG-AEWS1031 at http://portfolio.3ctn.ca


Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT01638533


Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02607813


Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/study/NCT02628067


A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02098967


Canadian Clinical Trials
US TRIALS


TK216 in Patients With Relapsed or Refractory Ewing Sarcoma (Ages 12 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02657005


Randomized Phase IIb Trial of Vigil™ Versus Gemcitabine + Docetaxel for Ewing's Sarcoma (Ages Older than 2 Years)

https://clinicaltrials.gov/ct2/show/NCT02511132


Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors (Ages 1 - 18 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01956669


Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours (TOPAZ) (Ages 2 - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02303028


HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors (Ages 1 to 40 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02557854


Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors (Ages 2 - 18 Years)

https://clinicaltrials.gov/show/NCT01858155
or search (C17) MEL P1 at http://portfolio.3ctn.ca


Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma (Ages 8 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02736565


The iCat2, GAIN Consortium Study (Ages Up to 30 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02520713


Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (Ages 1 - 30 Years)

https://clinicaltrials.gov/ct2/show/study/NCT02304458


Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma (Ages 18 and Older)\

https://clinicaltrials.gov/ct2/show/NCT01858168


SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02048371


ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma (Ages 13 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02044120


Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors (Ages 12 Months - 30 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02574728


Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT01858168


A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors (Ages 18 - 99 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02261220


Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors (Ages 18 and Older)

https://clinicaltrials.gov/ct2/show/NCT02298959
or search PJC-016/NCI 9676 at http://portfolio.3ctn.ca


A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/study/NCT02410512


A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT) (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02791334


A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051) (Ages 6 Months - 17 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02332668


A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (Ages Up to 21 Years)

https://clinicaltrials.gov/ct2/show/NCT00743496


Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (Ages Up to 50 Years)

https://clinicaltrials.gov/ct2/show/study/NCT02306161
or Search COG-AEWS1221 at http://portfolio.3ctn.ca


HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (Ages 7 - 30 Years)

https://clinicaltrials.gov/ct2/show/NCT00931931


A Single-Arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors (Up to 30 Years Old)

https://clinicaltrials.gov/ct2/show/study/NCT02541604


Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma (Ages 1 - 40 Years)

https://clinicaltrials.gov/ct2/show/NCT01864109


An Open-Label Study of Atezolizumab in Advanced Solid Tumors (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/study/NCT02458638


A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/study/NCT02219724


Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors (AflacST1402) (Ages 1 - 29 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02390843


Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR) (All Ages)

https://clinicaltrials.gov/ct2/show/NCT02100891


Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies (Ages 13 Months - 30 Years Old)

https://clinicaltrials.gov/ct2/show/study/NCT02116777


Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies (Ages 12 Months - 25 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02392793


TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate (Ages 7 Months - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02508038


Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma (Ewing/Allo) (Ages Up to 30 Years)

https://clinicaltrials.gov/ct2/show/NCT02472392


A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas (Ages 2 - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01625351


A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors (Up to 40 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01804634


Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501) (Ages 2 - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02644460


A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors (Up to 30 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02536183


Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors (Ages 12 Months - 20 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02013336


Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02607813


Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT01638533


Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02188264


Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours (Ages 18 - 99 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02482311


Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02737475


Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT01989585


A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors (Ages 18 - 99 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02261220


Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma (Ages Up to 50 Years)

Search COG-AEWS1031 at http://portfolio.3ctn.ca


Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (ASCR) (Ages 1 - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01661400


Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (Up to 70 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01505569


PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) (Ages 3 - 35 Years)

https://clinicaltrials.gov/ct2/show/NCT02390752


Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies (Ages 2 - 18 Years)

https://clinicaltrials.gov/ct2/show/NCT02432274


Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody (All Ages)

https://clinicaltrials.gov/ct2/show/NCT02159443


Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors (Ages 1 - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02689336


Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer (All Ages)

https://clinicaltrials.gov/ct2/show/NCT00445965


Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/study/NCT02628067


Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies (Ages 18 and Older)

https://clinicaltrials.gov/ct2/show/NCT01924689


Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) (Ages 18 and Older)

https://clinicaltrials.gov/ct2/show/study/NCT02568267


A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia (Ages 18 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02098967


Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma (All Ages)

https://clinicaltrials.gov/ct2/show/NCT01876303


Collecting and Storing Biological Samples From Patients With Ewing Sarcoma (Ages Up to 21 Years)

https://clinicaltrials.gov/ct2/show/study/NCT00899990


To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors (Ages 6 Months - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01962103


Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors (Ages 6 Months and Older)

https://clinicaltrials.gov/ct2/show/NCT02441062


Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) (UVA-Gen001) (Ages 1 - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02624388


Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI (Ages 8 - 40 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01336803


In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (Poly-ICLC) (Ages 18 and Older)

https://clinicaltrials.gov/ct2/show/NCT02423863


PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (PANAMA) (Ages 18 and Older)

https://clinicaltrials.gov/ct2/show/NCT02702492


NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy (Ages 18 and Older)

https://clinicaltrials.gov/ct2/show/NCT02319824


Advanced MR Imaging in Sarcoma Patients (Ages 7 Years and Older)

https://clinicaltrials.gov/ct2/show/NCT02705391


Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas (All Ages)

https://clinicaltrials.gov/ct2/show/NCT02415816


Molecular Analysis Of Solid Tumors (MAST) (Up to 25 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01050296


Methionine PET/CT Studies In Patients With Cancer (All Ages)

https://clinicaltrials.gov/ct2/show/NCT00840047


Molecular-Guided Therapy for Childhood Cancer (Ages 13 Months - 21 Years Old)

https://clinicaltrials.gov/ct2/show/NCT02162732


Genomic Analysis of Pediatric Bone Tumors (Up to 18 Years Old)

https://clinicaltrials.gov/ct2/show/NCT01047878